ImmunoGen, Inc.
(NASDAQ GS: IMGN)
Rigrodsky Law, P.A. is investigating ImmunoGen, Inc. (“ImmunoGen”) regarding possible breaches of fiduciary duties and other violations of law related to ImmunoGen’s agreement to be acquired by AbbVie Inc. Under the terms of the agreement, ImmunoGen shareholders will receive $31.26 per share in cash.